Bear starts Shire with $67 target

Bear Stearns analyst John Boris started coverage of Shire Pharmaceutical with an outperform rating and year-end 2007 price target of $67.The analyst projects three- and five-year incremental revenues of $1.1 billion and $1.4 billion, respectively. Shares of the Basingstoke, England-based pharmaceutical company up 14p, or 1.43%, at 993p. (London: SHP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.